XML 13 R2.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 20,779,152 $ 23,693,633
Short-term investments 107,216,498 57,538,852
Accounts receivable 2,783,264 3,316,361
Accounts receivable from affiliated entities 1,295,737 738,583
Prepaid expenses and other current assets 1,386,801 1,406,590
Prepaid expenses and other current assets from affiliated entities 1,441,546 1,120,805
Total current assets 134,902,998 87,814,824
Fixed assets, net 15,185,998 15,949,014
Investment in affiliated entity - GeneOne 6,430,383 6,381,926
Investment in affiliated entity - PLS 2,225,427 3,023,987
Intangible assets, net 4,493,582 4,760,145
Goodwill 10,513,371 10,513,371
Operating lease right-of-use assets 14,432,479  
Other assets 2,981,270 2,669,998
Total assets 191,165,508 131,113,265
Current liabilities:    
Accounts payable and accrued expenses 15,644,783 23,134,733
Accounts payable and accrued expenses due to affiliated entities 1,315,610 977,792
Accrued clinical trial expenses 7,159,243 5,671,764
Deferred revenue 110,694 223,577
Deferred revenue from affiliated entities 2,325 33,575
Deferred rent 0 1,065,387
Operating lease liability 1,888,804  
Deferred grant funding 1,279,005 4,165,848
Deferred grant funding from affiliated entities 14,583 27,083
Total current liabilities 27,415,047 35,299,759
Deferred revenue, net of current portion 141,803 150,793
Convertible senior notes 60,562,503 0
Deferred rent, net of current portion 0 8,518,207
Operating lease liability, net of current portion 21,990,881  
Deferred tax liabilities 24,766 24,766
Other liabilities 64,257 87,333
Total liabilities 110,199,257 44,080,858
Stockholders’ equity:    
Preferred stock 0 0
Common stock 97,934 97,226
Additional paid-in capital 727,166,934 707,794,215
Accumulated deficit (649,645,698) (620,426,436)
Accumulated other comprehensive income (loss) 290,310 (528,867)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 77,909,480 86,936,138
Non-controlling interest 3,056,771 96,269
Total stockholders’ equity 80,966,251 87,032,407
Total liabilities and stockholders’ equity $ 191,165,508 $ 131,113,265